The safety and tolerability profile for Fasenra in the MANDARA trial was consistent with the known profile of the medicine. 4 Approximately half of patients with EGPA have adult-onset severe ...
AstraZeneca’s FASENRA ® (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). 1 EGPA is a rare, immune-mediated ...